Recombinant Human Ly6/PLAUR domain-containing protein 3 (LYPD3)

^{In
Stock}

中文名稱：

人LYPD3重組蛋白
貨號：

CSB-EP013263HU
說明書：

MSDS Datasheet
規(guī)格：

￥1536
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 85% as determined by SDS-PAGE.
基因名：

LYPD3
Uniprot No.：

O95274
別名：

GPI-anchored metastasis-associated protein C4.4A homolog (Matrigel-induced gene C4 protein) (MIG-C4)
種屬：

Homo sapiens (Human)
蛋白長度：

Full Length of Mature Protein
來源：

E.coli
分子量：

37.1 kDa
表達(dá)區(qū)域：

31-326aa
氨基酸序列

LECYSCVQKADDGCSPNKMKTVKCAPGVDVCTEAVGAVETIHGQFSLAVRGCGSGLPGKNDRGLDLHGLLAFIQLQQCAQDRCNAKLNLTSRALDPAGNESAYPPNGVECYSCVGLSREACQGTSPPVVSCYNASDHVYKGCFDGNVTLTAANVTVSLPVRGCVQDEFCTRDGVTGPGFTLSGSCCQGSRCNSDLRNKTYFSPRIPPLVRLPPPEPTTVASTTSVTTSTSAPVRPTSTTKPMPAPTSQTPRQGVEHEASRDEEPRLTGGAAGHQDRSNSGQYPAKGGPQQPHNKGC
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 10xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder Warning: in_array() expects parameter 2 to be array, null given in /www/web/cusabio_cn/public_html/caches/caches_template/default/content/show_product_protein.php on line 662
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
復(fù)溶：

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
儲存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
產(chǎn)品描述：

Like all recombinant proteins, this Recombinant Human LYPD3 protein was encoded by recombinant DNA. The recombinant DNA was introduced to a plasmid in which the gene of LYPD3 was cloned downstream of a promoter region. When the plasmid was introduced to the cells of E.coli, the E.coli’s own protein synthesis pathways would then result in the expression of the LYPD3 protein. And the next step was protein purification. The purity of this recombinant protein is 85%+ determined by SDS-PAGE.
LYPD3 is a tumorigenesis and metastasis-associated cell surface protein that was found to be expressed in 50% of primary lung cancers and metastases on the transcriptional level. Meanwhile, the expression of LYPD3 is found to be upregulated in some of NSCLC subtypes such as squamous cell lung cancer. . Research on the correlation between LYPD3 and the occurrence of cancer has garnered increasing scientific attention. Studies have shown that LYPD3 can specifically participate in tumor cell invasion through its interaction with extracellular matrix. Moreover, the antibody–drug conjugate targeting LYPD3 has shown efficacy in mouse models of lung cancer. In addition, cases with hypermethylated LYPD3 have better prognosis and survival status, which confirms our conjecture. There is evidence that LYPD3 can promote the epithelial–mesenchymal transition (EMT) in the aggressive front of tumor tissues, which would lead to initiation and development of cancers and chemo-resistance of metastatic cancers.
Datasheet & COA：

Please contact us to get it.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
基因功能參考文獻(xiàn)：
1. While in the healthy liver hepatocytes are C4.4A negative, data show that C4.4A is strongly expressed in hepatocellular carcinoma (HCC) with upregulation at the invasive front and in lung metastasis, indicating that C4.4A apparently contributes to HCC progression. PMID: 29048672
2. Our results are consistent with previous data in mouse embryogenesis and wound healing. Based on these findings, we conclude that this human TES model provides an excellent surrogate for studies of C4.4A and Haldisin expressions in human stratified epithelia. PMID: 29075641
3. Expression and crystallographic studies of the D1D2 domains of C4.4A have been reported. PMID: 28777093
4. LYPD3 has a role in the maintenance of colorectal cancer stem-like cells. PMID: 28238780
5. Highly expressed C4.4A protein in HER2-positive human breast cancers indicate a good prognosis. PMID: 23918676
6. overexpression of C4.4A correlates with metastatic potential of gastric cancer and C4.4A could be a novel independent prognostic marker for predicting outcome. PMID: 24935570
7. expression of the Ly6/uPAR-domain proteins C4.4A and Haldisin in non-invasive and invasive skin lesions PMID: 25414274
8. Tenascin-C expression was significantly associated with C4.4A expression in clinical esophageal squamous carcinoma samples suggesting that there may be a functional role for the C4.4A to induceTenascin-C in vivo. PMID: 23708783
9. findings suggest that a tight association between C4.4A and tumor budding may, in part, be due to C4.4A promoting epithelial-mesenchymal transition at the invasive front of colorectal cancer PMID: 22404718
10. the first explanation for the C4.4A contribution to wound healing and metastasis. PMID: 22431918
11. data indicate that expression of the C4.4A protein at the invasive front acts as a novel prognostic marker in colorectal cancer, possibly through invasion-related mechanisms PMID: 20825414
12. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan PMID: 12592373
13. High tumour cell C4.4A expression is associated with shorter survival for non-small cell lung cancer patients. PMID: 17706320
14. Overexpression of C4.4A is associated with invasion and metastasis of esophageal squamous cell carcinoma PMID: 17849475
15. we consider C4.4A as a candidate diagnostic marker in colorectal cancer, which possibly can be detected in body fluids PMID: 17912244
16. cleavage of C4.4A by ADAM10 and ADAM17 contributes to tumor progression PMID: 18979631
顯示更多

收起更多
亞細(xì)胞定位：

Cell membrane; Lipid-anchor, GPI-anchor.
組織特異性：

Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TC
數(shù)據(jù)庫鏈接：

HGNC: 24880

OMIM: 609484

KEGG: hsa:27076

STRING: 9606.ENSP00000244333

UniGene: Hs.631594